Fotemustine/Dacarbazine Interactions
This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.
Medical warning:
Serious. These medicines may interact and cause very harmful effects. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
Fotemustine and dacarbazine are used together to treat certain cancers. When dacarbazine is given only a few hours before fotemustine, fotemustine may work better against your cancer, but it may also affect your lungs.
What might happen:
Fotemustine may damage your lungs. This damage may be severe and can result in death.
What you should do about this interaction:
When fotemustine and dacarbazine are used together to treat cancer, they are normally given on different days to allow your body to recover from the first drug. Discuss how you will be receiving these medicines with your healthcare professionals (e.g. doctor or pharmacist) and the risks and benefits of your therapy.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.
- 1.Gerard B, Aamdal S, Lee SM, Leyvraz S, Lucas C, D'Incalci M, Bizzari JP. Activity and unexpected lung toxicity of the sequential administration of two alkylating agents--dacarbazine and fotemustine--in patients with melanoma. Eur J Cancer 1993;29A(5):711-9.
- 2.Muphoran (fotemustine) Australian prescribing information. Servier August 21, 2001.
- 3.Aamdal S, Gerard B, Bohman T, D'Incalci M. Sequential administration of dacarbazine and fotemustine in patients with disseminated malignant melanoma--an effective combination with unexpected toxicity. Eur J Cancer 1992;28(2-3):447-50.
- 4.Lee SM, Margison GP, Woodcock AA, Thatcher N. Sequential administration of varying doses of dacarbazine and fotemustine in advanced malignant melanoma. Br J Cancer 1993 Jun;67(6):1356-60.
Selected from data included with permission and copyrighted by First Databank, Inc. This copyrighted material has been downloaded from a licensed data provider and is not for distribution, except as may be authorized by the applicable terms of use.
CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.